Drugs / TEGAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04093648 | Jan 2020 → Feb 2023 | hepatoblastoma | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEGAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093648 ↗ |
| Action | Deplete | “In this study the investigator will be testing the ability of GPC3-CAR cells to identify and kill tumor cells in patients.” NCT04093648 ↗ |
| Modality | Cell therapy | “special immune system cells called TEGAR T cells, a new experimental treatment.” NCT04093648 ↗ |
| Target | GPC3 | “In our preclinical studies, several genes were made called a chimeric antigen receptor (CAR), from an antibody called GC33 that recognizes glypican-3, a protein found on almost...” NCT04093648 ↗ |